Heart patients may have hidden lung disease – new study aims to find out

NCT ID NCT06909773

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study will screen 3,000 adults with heart disease (coronary artery disease, atrial fibrillation, or heart failure) to see how many also have COPD, a serious lung condition. Doctors and patients will receive education on managing both heart and lung problems together. The goal is to understand the overlap and whether co-management can reduce hospitalizations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: guideline education and implementation intervention
What this could lead to: If successful, this could show that combining heart and lung care reduces hospital readmissions for patients with both conditions.
What could go wrong: This is an early-stage study focused on education and screening, not a new drug or treatment. It may not lead to direct changes in patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Give signed written informed consent to participate. 2. At least 40 years of age at baseline visit. 3. Previous or newly diagnosed by at least one of the 3 types of CVD which are, * Coronary heart disease ( CHD ) * Atrial fibrillation (AF ) * Chronic heart failure ( CHF ) 4. Participants can undergo spirometry testing and does not have the following serious diseases or disease states： * Shock within the last 3 months * Mycardial infarction, stroke or unstable angina within last 1 month * Currently suffering from severe HF or severe arrhythmia. Severe HF refers to the need for intravenous administration of vasoactive drugs and diuretics; severe arrhythmia refers to arrhythmias that cause hemodynamic instability, such as ventricular fibrillation and ventricular tachycardia * Severe hemoptysis or active gastrointestinal bleeding within last 1 month * Patients with seizures requiring medication * Patients with hypertensive crisis or uncontrolled hypertension \[systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg (1 mmHg = 0.133 kPa)\] * Patients with active respiratory infectious diseases or infectious diseases, such as open pulmonary tuberculosis, influenza, new coronavirus infection, and acute pneumonia * Patients with aortic or cerebral aneurysms * Pneumothorax and pneumothorax healing within last 1 month * Patients with severe hyperthyroidism * Patients who have recently had eye, ear, cranial or thoracic or abdominal surgery Note: If the patient can cooperate by completing a single, effective forced exhalation (≥6 seconds), then spirometry testing can be performed. 5. Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators. Exclusion Criteria: 1. Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study. 2. Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception. 3. Participant who are not able to provide written informed consent. 4. Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation cardiovascular disorder congestive heart failure coronary artery disorder heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

85 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

Anqing, 246004, China
Research Site
RECRUITING

Beijing, 100029, China
Research Site
NOT_YET_RECRUITING

Beijing, 100029, China
Research Site
NOT_YET_RECRUITING

Beijing, 100037, China
Research Site
NOT_YET_RECRUITING

Beijing, 100050, China
Research Site
RECRUITING

Beijing, 100191, China
Research Site
NOT_YET_RECRUITING

Changsha, 410005, China
Research Site
RECRUITING

Changsha, 410300, China
Research Site
NOT_YET_RECRUITING

Chaohu, 238001, China
Research Site
RECRUITING

Chengdu, 610021, China
Research Site
RECRUITING

Chengdu, 610041, China
Research Site
RECRUITING

Chengdu, 610072, China
Research Site
RECRUITING

Chifeng, 024206, China
Research Site
RECRUITING

Chongqing, 400010, China
Research Site
NOT_YET_RECRUITING

Dalian, 116001, China
Research Site
NOT_YET_RECRUITING

Dingzhou, 562100, China
Research Site
NOT_YET_RECRUITING

Dongguan, 523009, China
Research Site
NOT_YET_RECRUITING

Foshan, CN-528000, China
Research Site
RECRUITING

Fuyang, 236400, China
Research Site
NOT_YET_RECRUITING

Fuzhou, 350005, China
Research Site
RECRUITING

Ganzhou, 341699, China
Research Site
NOT_YET_RECRUITING

Guanghan, 618300, China
Research Site
NOT_YET_RECRUITING

Guangzhou, 510080, China
Research Site
NOT_YET_RECRUITING

Guangzhou, 510100, China
Research Site
RECRUITING

Guangzhou, 510280, China
Research Site
NOT_YET_RECRUITING

Guangzhou, 510515, China
Research Site
RECRUITING

Haikou, 570311, China
Research Site
NOT_YET_RECRUITING

Hangzhou, 310016, China
Research Site
RECRUITING

Hangzhou, 310030, China
Research Site
RECRUITING

Harbin, 150001, China
Research Site
RECRUITING

Harbin, 150036, China
Research Site
NOT_YET_RECRUITING

Hefei, 230001, China
Research Site
RECRUITING

Hefei, 230011, China
Research Site
RECRUITING

Hubei, 434300, China
Research Site
RECRUITING

Jinhua, 321099, China
Research Site
NOT_YET_RECRUITING

Jinzhong, 030600, China
Research Site
RECRUITING

Jiujiang, 332000, China
Research Site
RECRUITING

Kaiyuan, 661600, China
Research Site
NOT_YET_RECRUITING

Kunming, 650032, China
Research Site
NOT_YET_RECRUITING

Kunming, 650101, China
Research Site
RECRUITING

Lanzhou, 730000, China
Research Site
RECRUITING

Leping, 333300, China
Research Site
NOT_YET_RECRUITING

Lianjiang, 524400, China
Research Site
RECRUITING

Linhai, 317000, China
Research Site
RECRUITING

Meizhou, 514031, China
Research Site
RECRUITING

Mianyang, 621000, China
Research Site
RECRUITING

Nanchang, 330006, China
Research Site
NOT_YET_RECRUITING

Neijiang, 641200, China
Research Site
RECRUITING

Ningbo, 315600, China
Research Site
NOT_YET_RECRUITING

Ningbo, 315700, China
Research Site
RECRUITING

Putian, 351106, China
Research Site
NOT_YET_RECRUITING

Quanzhou, 362000, China
Research Site
RECRUITING

Shanghai, 200072, China
Research Site
NOT_YET_RECRUITING

Shanghai, 200080, China
Research Site
RECRUITING

Shanghai, 201114, China
Research Site
NOT_YET_RECRUITING

Shanghai, 201199, China
Research Site
RECRUITING

Shanghai, 201318, China
Research Site
RECRUITING

Shantou, 515031, China
Research Site
NOT_YET_RECRUITING

Shantou, 515041, China
Research Site
NOT_YET_RECRUITING

Shenyang, 110004, China
Research Site
NOT_YET_RECRUITING

Shenzhen, 518036, China
Research Site
RECRUITING

Shijiazhuang, 50051, China
Research Site
RECRUITING

Sichuan, 643200, China
Research Site
RECRUITING

Suining, 629000, China
Research Site
RECRUITING

Suzhou, 215300, China
Research Site
RECRUITING

Taiyuan, 030001, China
Research Site
NOT_YET_RECRUITING

Taiyuan, 030032, China
Research Site
RECRUITING

Tai’an, 271000, China
Research Site
NOT_YET_RECRUITING

Tianjin, 300050, China
Research Site
RECRUITING

Tianjin, 300211, China
Research Site
NOT_YET_RECRUITING

Tianjin, 300222, China
Research Site
NOT_YET_RECRUITING

Tianmen, 431700, China
Research Site
RECRUITING

Wuhan, 430000, China
Research Site
NOT_YET_RECRUITING

Wuhan, 430000, China
Research Site
NOT_YET_RECRUITING

Wuxi, 214122, China
Research Site
RECRUITING

Xi'an, 710100, China
Research Site
RECRUITING

Xiamen, 361003, China
Research Site
RECRUITING

Xiangyang, 441000, China
Research Site
RECRUITING

Xinzheng, 451100, China
Research Site
RECRUITING

Xuzhou, 221009, China
Research Site
RECRUITING

Yangzhou, 225001, China
Research Site
RECRUITING

Yulin, 537000, China
Research Site
RECRUITING

Zhangzhou, 363099, China
Research Site
NOT_YET_RECRUITING

Zhengzhou, 450000, China
Research Site
RECRUITING

Zunyi, 563100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.